Clinical trial · Observational
the Oncogenic Potential of Salivary miRNA-93 and miRNA-412-3P in Oral Lichen Planus Patients
NCT05400057CI-TRIAL-00070323completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Assessment The oncogenic potential of salivary microRNA-93 and microRNA-412-3p in oral lichen planus
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Cancer | Malignant Lip and Oral Cavity Neoplasm | CURATED_BROADER | 0.80 |
| Oral Lichen Planus | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- group 1
- description
- Oral Lichen Planus patients. Patients will be diagnosed clinically and histologically.
- label
- Group 2
- description
- Healthy patients. Patients without any systemic or oral lesions, not taking drugs for at least the the last 6 months
- label
- Group 3
- description
- Oral Squamous Cell Carcinoma
Primary outcomes (2)
- measure
- miRNA-93
- timeFrame
- 2 years
- description
- MicroRNA 93 is a functional RNA and a microRNA that in humans is encoded by the MIR93 (MicroRNA 93) gene
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Both genders with age range from 40 to 70 years. * Clinically diagnosed and histologically confirmed as having symptomatic OLP. * Patients who agree to sign a written consent after understanding the nature of the study Exclusion Criteria: * -Systemic and/or local systemic drug therapy within the last 3 months prior to the start of the study * Patients on steroidal or non-steroidal anti-inflammatory drugs (NSAIDs) for at least the last 6 months * Patients on Retinoid, green tea supplements or another natural products therapy * Patients with already diagnosed malignant lesion/lesions * Pregnant or Lactating females * Vulnerable groups as prisoners, mentally disabled, etc…
References
Publications (0)
Data not yet available
No reference posted for this study.